Ticker Details
Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat.
IPO Date:	July 31, 1996
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$976.56M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.13 | 3.40%
Avg Daily Range (30 D):	$0.05 | 3.13%
Avg Daily Range (90 D):	$0.04 | 3.01%

Institutional Daily Volume
Avg Daily Volume:	3.19M
Avg Daily Volume (30 D):	8.63M
Avg Daily Volume (90 D):	11.56M

Trade Size
Avg Trade Size (Sh.):	334
Avg Trade Size (Sh.) (30 D):	166
Avg Trade Size (Sh.) (90 D):	149

Institutional Trades
Total Institutional Trades:	3,039
Avg Institutional Trade:	$1.81M
Avg Institutional Trade (30 D):	$1.17M
Avg Institutional Trade (90 D):	$1.35M
Avg Institutional Trade Volume:	.66M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.16M
Avg Closing Trade (30 D):	$1.31M
Avg Closing Trade (90 D):	$1.43M
Avg Closing Volume:	832.7K

News

May 20, 2026 @ 1:50 PM Cell-Based Therapies Poised to Disrupt Multi-Billi... Source: Market News Updates

Apr 22, 2026 @ 11:00 AM Geron Plans to Announce First Quarter 2026 Financi... Source: Na

Apr 13, 2026 @ 12:00 PM Geron Announces Appointment of Timothy Williams as... Source: Geron Corporation

Apr 6, 2026 @ 12:00 PM Geron to Participate in the 25th Annual Needham Vi... Source: Na

Feb 25, 2026 @ 12:00 PM Geron Corporation Reports Fourth Quarter and Full ... Source: Na

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.11	$-.02	$-.01
Diluted EPS	$-.11	$-.02	$-.01
Revenue	$204.56M	$57.48M	$51.84M
Gross Profit
Net Income / Loss	$-67.61M	$-16.68M	$-3.64M
Operating Income / Loss	$-51.77M	$-12.5M	$.16M
Cost of Revenue
Net Cash Flow	$-15.07M	$-6.25M	$-8.66M
PE Ratio